|
|
 |
|
Viewing report
|
|
|
|
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
Espicom Business Intelligence Ltd, March 2009, Pages: 206
A comprehensive examination of the non-small cell lung cancer market and therapeutic approaches
Although a plethora of platinum-based chemotherapy combinations may be prescribed for the treatment of non-small cell lung cancer (NSCLC), the market is currently driven by chemotherapeutic agents such as the taxanes and antimetabolites, and the increasing use of targeted therapies. Some of the newer chemotherapy agents, such as Eli Lilly’s Gemzar and Alimta, have become the standard of care in combination with cisplatin or carboplatin and may be used in addition to or instead of the taxanes, Taxotere or Taxol/generic paclitaxel.
As researchers begin to understand the processes involved in NSCLC formation, several new targeted therapies have evolved that modulate growth factor pathways. Roche/Genentech's small-molecule tyrosine kinase inhibitor, Tarceva (erlotinib), and its anti-angiogenic VEGF inhibitor, Avastin (bevacizumab), are gaining credence in second- and first-line therapy, respectively.
Intense research is producing new approaches
NSCLC is one of the most actively researched cancers, with approximately 110 drugs in the US being evaluated in clinical trials. The drugs span a variety of drug classes and whilst some represent new formulations of existing brands, others offer novel approaches to targeting angiogenesis or cell death. The much awaited cancer vaccines are now in Phase III, with first launch expected in 2012.
By 2014, it is expected that at least five new chemotherapeutic agents will be launched to be used in combination with existing treatment protocols and, in some cases, may replace older products, including: Abraxis BioSciences' Abraxane and Cell Therapeutics/Novartis' Opaxio, both new formulations of paclitaxel; the third-generation platinum-based therapies, sanofi-aventis’ Eloxatin and GPC Biotech's satraplatin; and Bristol-Myers Squibb's epothilone analogue, Ixempra.
The addressable NSCLC market will increase by 9.8% by 2014. What are the current and new products that will drive commercial growth and what are the therapeutic approaches to watch?
Lung cancer affects over 1.4 million patients. Non-small cell lung cancer, which accounts for approximately 87% of all lung cancers, is one of the leading causes of death, killing more patients than breast, colon and prostate cancer together and accounting for nearly 30% of all cancer deaths. Survival rates are among the worst for any cancer with a large and growing unmet clinical need.
A changing approach
The NSCLC market is set for radical change. A number of current first-line therapies will become subject to generic competition in the short term and, although chemotherapy will continue to play a significant if diminishing role, industry attention is firmly on the better tolerated biologics, which are already setting the pace in the market and whose influence will grow over the coming years. In 2007, chemotherapy treatments accounted for 68% of the market, but are forecast to account for only 36% by 2014. Targeted treatments are forecast to increase from 32% to 60% over the same period.
Impact on the industry
Roche/Genentech – currently the dominant player in the sector – will move into an even more commanding position, accounting for 42% of the market through the ongoing sales and development of leading products such as Avastin and Tarceva. The market will be more diverse, with 12 companies taking more than 1% market share in 2014, as opposed to 6 in 2007.
Vaccines
The benefits of lung cancer vaccines remain significant, but without launch and experience of large patient populations in post-launch, they remain just a promise. Of the candidates in Phase III, Merck’s Stimuvax is expected to be first to market in 2012, with GSK’s MAGE-A3/GSK1572932A following on.
On the horizon: new Phase II approaches show promise
Targeting TRAIL (TNF-related apoptosis-inducing ligand) receptors is one avenue that is currently being explored by a number of companies. TRAIL induces apoptosis via two death domain-containing receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5). Human Genome Sciences' mapatumumab is the most advanced death receptor activator currently under development, while other candidates with potential include: Amgen's AMG 655, Amgen/Genentech's AMG 951 and Genentech's apomab.
This unbeatable executive report provides…
- A comprehensive review of the market, disease incidence and growth
- An evaluation of the current understanding of non-small cell lung cancer
- A comparison of the corporate and competitive landscape in 2007 and 2014
- Detailed analysis and 5-year sales forecasts for current products by value
- A detailed review of up and coming products with 5-year forecasts from year of launch
- Unique product assessment and scoring
CURRENT PRODUCTS EVALUATED & FORECAST
- Taxol (BMS)
- Taxotere (sanofi-aventis)
- Alimta (Eli Lilly)
- Gemzar (Eli Lilly)
- Iressa (AstraZeneca)
- Tarceva (Roche/Genentech/OSI)
- Avastin (Roche/Genentech/Chugai)
LATE-PHASE PRODUCTS EVALUATED AND FORECAST
- Abraxane (Abraxis)
- Opaxio (Novartis)
- Erbitux (Eli Lilly/BMS)
- Figitumumab (Pfizer)
- Aflibercept (sanofi-aventis/Regeneron)
- Nexavar (Bayer/Onyx)
- Sutent (Pfizer)
- Tovok (Boehringer Ingelheim)
- Vargatef (Boehringer Ingelheim)
- Zactima (AstraZeneca)
- ASA404 (Novartis)
Vaccines
- Lucanix (NovaRx)
- MAGE-A3 (GSK)
- Stimuvax (Merck KGaA)
NOVEL PHASE II PRODUCTS EVALUATED INCLUDE
Angiogenesis Inhibitors
- Recentin (AstraZeneca)
- Armala (GSK)
- ABT-869 (Abbott/Genentech)
- Axitinib (Pfizer)
- IMC-1121B (Eli Lilly)
Death Receptor Agonists
- AMG 655 (Amgen/Genentech)
- AMG 951 (Amgen/Genentech)
- Apomab (Genentech)
- Mapatumumab (Human Genome Sciences)
Customers who bought this item also bought
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline Set To Offer Only Modest Improvements
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
Non-Small Cell Lung Cancer - Avastin to Lead the Market
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
Targeted Therapeutics in Non-Small Cell Lung Cancer
Stakeholder Insight: Non-Small Cell Lung Cancer - The Need for Greater Product Differentiation in an Increasingly Crowded Market
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma - Limited R&D Activity Provides Opportunity for Early-Phase Pipeline Drugs
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies - More Drugs on the Market, More Targets in the Pipeline
Cancer Therapies - Global Strategic Business Report
Targeted Cancer Therapies: Innovative Drugs And Their Impact On The Future Of Oncology
|
|
|
|
